MedWatch

Oncology Venture ready for turning Novartis candidate into precision medicine

Danish biotech firm Oncology Venture has fine-tuned its DRP technology to become better at predicting which patients will benefit from treatment with Novartis' candidate dovitinib against cancer in the kidneys and uterus.

Foto: Oncology Venture, PR

Danish Oncology Venture has turned its attention to the cancer candidate dovitinib, which was acquired from Swiss drug group Novartis and already showed good results in a phase III trial, writes the company in a press release.

Oncology Venture successfully fine-tuned its drug response predictor (DRP) technology to identify which patients will benefit from treatment with dovitinib.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier